Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
Calithera Biosciences, Inc. logo

OTC · CALA

Calithera Biosciences, Inc.

Healthcare · Biotechnology

$0.00

Up+$0.00 (+0.00%)

Updated Oct 7, 2026, 3:17 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
487
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.00 – $0.01
Volume
1.04K
Avg. volume
2.02K

Price performance · CALA

CALA price history

1M range · 8 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

CALA closed at $0.00 after 8 trading sessions, down 75.00% for the selected period.

Last close
$0.00
Period change
-75.00%
Period low
$0.00
Period high
$0.00
Daily close
View OHLC price history
CALA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$0.0001$0.0001$0.0001$0.00011.04K
Oct 2, 2026$0.0001$0.0001$0.0001$0.0001307
Oct 1, 2026$0.0001$0.0001$0.0001$0.0001166
Sep 30, 2026$0.0003$0.0003$0.0003$0.0003265
Sep 17, 2026$0.0003$0.0003$0.0003$0.00032.24K
Sep 14, 2026$0.0003$0.0003$0.0003$0.0003327
Sep 10, 2026$0.0001$0.0001$0.0001$0.0001300
Sep 8, 2026$0.0003$0.0004$0.0003$0.0004625

Latest CALA news

The latest Smart Investors Daily articles mentioning CALA.

Stock researchCompany · Overview

CALA research

Overview

Company profile and research snapshot.

Company profile

CALITHERA BIOSCIENCES INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
CALA recent ratings
DateFirmRatingTarget
Nov 15, 2022Ladenburg ThalmannNeutral—
Nov 15, 2022SVB LeerinkMarket Perform—
Aug 29, 2022HC Wainwright & Co.Buy—
Aug 16, 2022SVB LeerinkOutperform—
May 11, 2022Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Jan 9, 2023

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that it is in the best interests of its shareholders to dissolve the Company and liquidate its assets, following an orderly wind down of the company’s operations. In order to reduce costs and in connection with the planned dissolution, Calithera is discontinuing all clinical development programs and reducing its workforce, including the termination of most employees by the end of the first quarter.

GlobeNewswire Inc. · Nov 8, 2022

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

GlobeNewswire Inc. · Sep 6, 2022

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By